Navigation Links
Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results
Date:2/8/2010

9,995) 29,808 Other expenses -- (26,975) (39,510) (54,695) Total other expenses (10,443) (11,411) (59,505) (24,887) Income before provision for income tax 3,141,317 2,465,947 5,837,975 4,615,789 Provision for income tax 571,756 408,827 1,081,691 767,677 Net income 2,569,561 2,057,120 4,756,284 3,848,112 Less: Net income attributable to noncontrolling interest 1,485 -- (1,040) -- Net income attributable to Tianyin 2,568,076 2,057,120 4,757,324 3,848,112 Other comprehensive income Foreign currency translation adjustment 10,927 256,933 46,784 346,367 Comprehensive income $2,579,003 $2,314,053 $4,804,108 $4,194,479 Basic earnings per share $0.10 $0.11 $0.20 $0.20 Diluted earnings per share $0.08 $0.13 $0.17 $0.16 Weighted average number of common shares outstanding Basic 24,906,965 15,691,495 22,323,116 15,637,623 Diluted 30,439,912 15,691,495 28,521,127 24,697,018 Consolidated Statements of Cash Flows (Unaudited) For the Six Months Ended December 31, 2009 2008 Cash flows from operating activities: Net Income $4,757,324 $3,848,112 Adjustments to reconcile net income to net cash provided by (used in) operating activities: Depreciation and amortization 393,575 237,619 Noncontro
'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
2. Tianyin Pharmaceutical Co., Inc. to Host Fiscal 2009 Earnings Conference Call on Thursday, September 24, 2009 at 10:30 a.m. ET
3. Tianyin Pharmaceutical Co., Inc. Obtains GMP Certification for Its New Production Facility
4. Tianyin Pharmaceutical, Co. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 11 at 10:50 am ET
5. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets
6. Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders
7. Tianyin Pharmaceutical Co., Inc. Adopts New Sales Strategy for Azithromycin Dispersible Tablets
8. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Wednesday, February 18, 2009 at 8:45 a.m. EST
9. Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth
10. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
11. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 The announced sales of three healthcare ... looking to expand in non-healthcare areas, says Kalorama Information. ... research firm says that  Siemens is the third largest ... of the IVD market , with 5.5 billion in ... composition would likely affect IVD market shares.  ...
(Date:11/26/2014)... The ETC (Emerging Technology Centers) http://www.etcbaltimore.com ... today that applications for AccelerateBaltimore™ (AB) 2015 program ... have a big idea?,” asked ETC’s President Deb ... it. AccelerateBaltimore helps you and your big idea ... weeks.” Interested game changers with “big ideas” ...
(Date:11/26/2014)... CA (PRWEB) November 25, 2014 Silicon ... joins forces with RPM Alliance , provider of ... pharmaceutical companies. With the latest addition to its CRO ... free validated EDC system to India. , “We ... a robust and customizable EDC platform which is both ...
(Date:11/26/2014)... 25, 2014 Miles Holder, formerly of ... Graphel Carbon Products team as Sales/Marketing Manager. Mr. Holder ... customer service for the graphite industry. , “We are ... team,” stated Dave Trinkley, VP of Market and Product ... of experience in the graphite industry, along with his ...
Breaking Biology Technology:Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2
... ADHD symptom control demonstrated from the first time point ... , PHILADELPHIA, June 1 Shire plc ... specialty biopharmaceutical company, today announced that the US Food ... the prescribing information for its once-daily Attention Deficit Hyperactivity ...
... MedImmune Plans to Begin Shipping Seasonal Vaccine to Health ... Md., June 1 MedImmune announced today that the ... awarded the company a contract to manufacture monovalent (single-strain) ... to vaccinate priority populations identified by HHS in the ...
... ALISO VIEJO, Calif., June 1 Valeant Pharmaceuticals International (NYSE: ... Phase IIb dose-finding clinical trial for taribavirin, a prodrug of ... hepatitis C in conjunction with a pegylated interferon. The ... standard design, consisting of 48 weeks of treatment with a ...
Cached Biology Technology:FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 2FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 3FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 4FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 5FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 6FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 7HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A (H1N1) 2HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A (H1N1) 3HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A (H1N1) 4Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 2Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 3Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 4
(Date:11/7/2014)... 6, 2014 Leading Biometric companies aim ... security revolutionizing online transactions.  Companies in focus today are: NXT-ID, ... BABA ), Google Inc. (NASDAQ: GOOG ... (NASDAQ: EBAY ) and MasterCard Inc. (NYSE: MA) ... NXTDW), a biometric authentication company focused on the growing mobile ...
(Date:11/5/2014)... Fidel Santamaria, associate professor of biology in the ... researchers in the nation selected to receive a ... Grant for Exploratory Research (EAGER). The funding supports ... support researchers to create new technology that will ... Santamaria, complex behaviors in neuroscience are broken into ...
(Date:11/4/2014)... Medicine announced today that it is a Grand ... Bill & Melinda Gates Foundation. Laura Goetzl, ... Sciences; and Vice Chair of Research and Academic ... pursue an innovative global health and development research ... Neurodevelopment.", Grand Challenges Explorations (GCE) funds individuals worldwide ...
Breaking Biology News(10 mins):Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3Temple University School of Medicine receives Grand Challenges Explorations grant 2
... LA JOLLA, Calif., September 12, 2012 The California ... million grant to Huei-Sheng Vincent Chen, Ph.D., associate professor ... one of 28 new projects funded as part of ... research aimed at increasing our understanding of stem cells ...
... in French . , Researchers from Sainte-Justine ... several novel genes that make some children more efficient ... to malaria infection. This world-first in integrative efforts to ... malaria and ultimately to identify the most suitable targets ...
... nuclear fusion reactors has the promise to be safe, sustainable ... fusion energy to the commercial energy market. This is partly ... known. A team of researchers at the University of ... seven other institutions, is trying to change that. Led ...
Cached Biology News:California's stem cell agency boosts heart disease research at Sanford-Burnham 2Genetic make-up of children explains how they fight malaria infection 2University of Tennessee, ORNL lead national team to study nuclear fusion reactors 2University of Tennessee, ORNL lead national team to study nuclear fusion reactors 3
Anti-MMP-7, aminoterminal end active enzyme; rabbit host...
Lipid Phosphate Phosphohydrolase 2...
ANTI-HUMAN CYTOKINES, GROWTH FACTORS (polyclonal rabbit (or goat) antibodies) Human TARC - Biotin...
Rabbit polyclonal to Glutathione S Transferase alpha ( Abpromise for all tested applications). Antigen: Full length protein: Human Glutathione S Transferase alpha. Entrez GeneID: 2938 Swi...
Biology Products: